1.Change of T lymphocyte subsets and their different apoptosis in acute pancreatitis
Chinese Journal of Hepatobiliary Surgery 2008;14(8):569-571
Objective To investigate the dynamic change and different apoptosis of T lymphocyte subsets in patients with acute pancreatitis.Methods Forty-four patients with MAP and 32 with SAP were enrolled in this study.Blood samples were collected on the lst,3rd and 7th d after onset.T lymphocyte subsets and their apoptotic rate were determined by flow cytometry.Results Compared with the control group and MAP group,CD4+ T lymphocytes and the ratio of CD4+/CD8+remarkably decreased while the apoptotic rate of CD4+ T cells significantly increased in patients with SAP.However,there was no marked difference in apoptotic rate of CD8+ T cells among different groups.Conclusion The different apoptosis of T lymphocyte subsets in AP,especially in SAP,results in severe and sustained cellular immune suppression.
2. Oral rehydration salt powder II effervescent tablets: Preparation and quality control
Academic Journal of Second Military Medical University 2011;32(5):528-531
Objective: To develop and prepare oral rehydration salt powder II (ORS II) effervescent tablets. Methods: Taking the mass/tablet, rigidity, disintegration time, and pressing status as the main indicators, we optimized the formulation and preparation process of the effervescent tablet by single factor test. The character, identification, disintegration time, acidity, and content determination of the tablets were also investigated. Results: It was found that the optimized preparation process of the effervescent tablets was to mix the acid part, which was granulated with ethanol, with the base part, and then compressed the mixture. The optimal formula was composed of: NaCl (11.5%), KCl (4.93%), C6H8O7 (6.21%), NaHCO3 (8.15%), C6 H12 O6 (65.7%), and PEG-6000 (3%). The rigidity of the prepared effervescent tablet was 4.5 kg and the disintegration time was 175 s. Conclusion: The formulation of the present product is consistent with the corresponding Chinese Pharmacopoeia monograph, requiting no additional effervescent; the preparation process is simple and the products are stable, and the product my be developed into a new oral rehydration salt formulation.
3.Classification and clinical study of plasma cell mastitis under breast duct endoscope.
Hong-chuan JIANG ; Ke-you WANG ; Jie LI ; Kai-tao YOU ; Jian-tao KOU
Chinese Journal of Surgery 2004;42(3):163-165
OBJECTIVETo evaluate the clinical significance of breast duct endoscope for plasma cell mastitis.
METHODSBreast duct endoscope was performed on 250 patients with nipple discharge. The characters of 95 cases of plasma cell mastitis under the breast duct endoscope were analyzed and studied.
RESULTSAmong the 95 cases with plasma cell mastitis, 21 were in type I, 43 in type II, 18 in type III and 13 in type IV. Eighty-three cases were treated with no-operation treatment, and 45 completely released, 38 partly released. There were 5 cases with middle to serious atypical hyperplasia in 12 cases treated with operation, that were all confirmed by pathological examination.
CONCLUSIONIn patients with plasma cell mastitis, clear diagnosis can be made through breast duct endoscope, and the breast duct with lesions could be positioned. It is a necessary assistant method for patients to avoid biopsy or decrease the biopsy range.
Adolescent ; Adult ; Aged ; Breast ; pathology ; Endoscopy ; Female ; Humans ; Mastitis ; pathology ; Middle Aged ; Plasma Cells ; pathology
4.Survey of Hepatitis B infection and vaccination status among drug users in Xi'an.
Qian WU ; Jian ZU ; Xiaoli WEI ; Lijuan YOU ; Lingling KOU ; Hengxin LI ; Guihua ZHUANG
Chinese Journal of Preventive Medicine 2014;48(10):862-866
OBJECTIVETo explore seroepidemiological status and vaccine coverage of hepatitis B among drug users in Xi'an.
METHODS545 drug users in the Xi'an Compulsory Detoxification Center were asked to answer questionnaire and provide blood sample (3-5 ml) for test of HBsAg, anti-HBc and anti-HBs from March to June 2013. Totally, 545 subjects were surveyed and tested. All of them effectively completed the survey.
RESULTSThe positive rates of HBsAg, anti-HBc and anti-HBs were 29.4% (160/545), 60.0% (327/545) and 56.1% (306/545), respectively. Eighty five subjects (15.6%) were negative for all of the three markers. The prevalence of HBsAg and anti-HBc among injection drug users were 40.0% (94/235) and 65.6% (154/235), which was significantly higher than non- injection drug users' (21.6% (52/241), 58.5% (141/241)) and mixed non-injection and injection drug users ((20.3% (14/69), 46.4% (32/69)) (χ(2) = 23.518 and 9.017, respectively, P < 0.05) . The HBsAg positive rate (30.6% (153/500)) of subjects with more than once per day of drug using within one year was significantly higher than those who used drugs for 2-3 times per week (15.6% (7/45)) (χ(2) = 4.51, P < 0.05). Only 11.7% (64/545) of drug users had a clear history of hepatitis B vaccination. The vaccination rate of subjects (3.5% (5/141)) with primary education or below was significantly lower than those with high school (16.3% (45/276)) (χ(2) = 26.61, P < 0.05). The vaccination rate of subjects (7.8% (12/153)) over 45 years old was significantly lower than that of subjects below 30 years old (15.9% (21/132)) and 30-44 years old (11.9% (31/260)) (χ(2) = 30.36, P < 0.05). The vaccinees had a significantly higher positive rate of anti-HBs (73.4% (47/64)) than those who without vaccination (53.8% (259/481)) (χ(2) = 8.81, P = 0.003), but the positive rates of HBsAg (16.7% (11/64)) were lower than those who without vaccination (31.0% (149/481)) (χ(2) = 23.52 and 9.02, respectively;P > 0.05).
CONCLUSIONThe HBV infection status among drug users in Xi'an was in serious condition, while a low vaccination rate was also discovered among them.
Adult ; Age Factors ; China ; epidemiology ; Drug Users ; Hepatitis B ; epidemiology ; Hepatitis B Antibodies ; Hepatitis B Surface Antigens ; Hepatitis B Vaccines ; Humans ; Middle Aged ; Prevalence ; Risk Factors ; Substance Abuse, Intravenous ; epidemiology ; Vaccination
5.Self-compassion in patients after colorectal cancer surgery:current situations and influencing factors
Shuang LI ; Mengying JIA ; Chaoxiang YOU ; Lili CHEN ; Hongyan KOU ; Shoujiang WEI
Modern Clinical Nursing 2023;22(10):8-15
Objective To investigate the current situations and analyse the influencing factors of self-compassion in patients 3 months after colorectal cancer surgery,so as to provide a basis for clinical interventions.Methods This cross-sectional survey was conducted from August 2020 to January 2022 among 190 patients who were at 3 months after colorectal cancer surgery in a tertiary hospital in sichuan.General information questionnaire,self-compassion scale,Connor-Davidson resilience scale and meaning in life questionnaire were used in the survey.Results Total scores of self-compassion,mental toughness and meaning of life after colorectal cancer surgery were 76.69±9.68,58.01±12.54 and 36.02±12.22,respectively.With analysis of multiple linear regression,the influencing factors of self-compassion were found as comorbid chronic diseases,postoperative stoma,postoperative radiotherapy,mental toughness and meaning of life(all P<0.05),toally explaining 58.4%its varience.Conclusions The self-compassion of patients with colorectal cancer is at a moderately lower level and the influencing factors of it include comorbid chronic diseases,postoperative stoma,postoperative radiotherapy,mental toughness and meaning of life.Medical staff should assess the psychological status of the patients,strengthen a psychological care and help patients to gain correct cognitive views for the purpose to improve the self-compassion of patients.
6.Research progress on pharmacokinetics and toxicity of vinorelbine
Hua LIU ; Yanshen CHEN ; Huining YOU ; Yan FENG ; Min LI ; Jianrong KOU ; Junsong WEI ; Weiyi FENG
China Pharmacy 2022;33(11):1403-1408
Vinorelbine(NVB)is a semisynthetic vinca alkaloid and can play an anti-tumor role by inhibiting the synthesis of tubulin. Its oral preparation has been used in the treatment of a variety of tumors as its convenience and good clinical response. The blood concentration of NVB is closely related to its curative effect and toxicity. Small variations in blood concentration may reduce the curative effect and even produce serious toxicity. There are some risks in the clinical drug use due to limited clinical data and effective pharmacodynamic monitoring methods. By reviewing the relevant literature at home and abroad ,this paper summarizes the research progress of in vivo pharmacokinetics and toxicity of NVB ,fully understands the pharmacokinetic characteristics and influencing factors of NVB ,the influencing factors of toxicity ,and the application status of pharmacokinetics in the adjustment of administration scheme ,so as to provide reference for its clinical rational use.
7.Long Noncoding RNA Expression Signatures of Abdominal Aortic Aneurysm Revealed by Microarray.
Yao Guo YANG ; Mei Xia LI ; Lei KOU ; You ZHOU ; Yan Wen QIN ; Xiao Jun LIU ; Zhong CHEN
Biomedical and Environmental Sciences 2016;29(10):713-723
OBJECTIVEThis study is aimed at observing the role of long noncoding RNAs (lncRNAs) in the pathogenesis of abdominal aortic aneurysm (AAA).
METHODSLncRNA and mRNA expression signatures of AAA tissues and normal abdominal aortic tissues (NT) were analyzed by microarray and further verified by Real-time quantitative reverse-transcription PCR (qRT-PCR). The lncRNAs-mRNAs targeting relationships were identified using computational analysis. The effect of lnc-ARG on 5-lipoxygenase (ALOX5) expression was tested in HeLa cells.
RESULTSDifferential expressions of 3,688 lncRNAs and 3,007 mRNAs were identified between AAA and NT tissues. Moreover, 1,284 differentially expressed long intergenic noncoding RNAs and 206 differentially expressed enhancer-like lncRNAs adjacent to protein-coding genes were discerned by bioinformatics analysis. Some differentially expressed lncRNAs and mRNAs between AAA and normal tissue samples were further verified using qRT-PCR. A co-expression network of coding and noncoding genes was constructed based on the correlation analysis between the differentially expressed lncRNAs and mRNAs. In addition, the lnc-ARG located within the upstream of ALOX5 was sorted as a noncoding transcript by analyzing the protein-coding potential using computational analysis. Furthermore, we found that lnc-ARG can decrease the mRNA level of ALOX5 and reactive oxygen species production in HeLa cells.
CONCLUSIONThis study revealed new lncRNA candidates are related to the pathogenesis of AAA.
Aged ; Aortic Aneurysm, Abdominal ; genetics ; metabolism ; Female ; Gene Expression Profiling ; Humans ; Male ; Middle Aged ; Oligonucleotide Array Sequence Analysis ; RNA, Long Noncoding ; genetics ; metabolism
8.Adherence to adjuvant with therapy imatinib in patients with gastrointestinal stromal tumor: a national multi-center cross-sectional study.
Peng ZHANG ; Jun ZHANG ; Bo ZHANG ; Wen Chang YANG ; Jun Bo HU ; Xiao Feng SUN ; Gang ZHAI ; Hao Ran QIAN ; Yong LI ; Hao XU ; Fan FENG ; Xing Ye WU ; He Li LIU ; Hong Jun LIU ; Hai Bo QIU ; Xiao Jun WU ; Yan Bing ZHOU ; Kun Tang SHEN ; You Wei KOU ; Yang FU ; Zhi Gang JIE ; Xiao Ming ZOU ; Hui CAO ; Zhi Dong GAO ; Kai Xiong TAO
Chinese Journal of Gastrointestinal Surgery 2021;24(9):775-782
Objective: To analyze the current adherence to imatinib in patients with gastrointestinal stromal tumors (GIST) in China and its influencing factors. Methods: A cross-sectional survey was conducted. Study period: from October 1, 2020 to November 31, 2020. Study subjects: GIST patients taking imatinib who were diagnosed and treated in public tertiary level A general hospitals or oncology hospitals; those who had not been pathologically diagnosed, those who never received imatinib, or those who had taken imatinib in the past but stopped afterwards were excluded. The Questionnaire Star online surgery platform was used to design a questionnaire about the adherence to adjuvant imatinib therapy of Chinese GIST patients. The link of questionnaire was sent through WeChat. The questionnaire contained basic information of patients, medication status and Morisky Medication Adherence Scale. Results: A total of 2162 questionnaires from 31 provinces, autonomous regions, and municipalities were collected, of which 2005 were valid questionnaires, with an effective rate of 92.7%. The survey subjects included 1104 males and 901 females, with a median age of 56 (22-91) years old. Working status: 609 cases (30.4%) in the work unit, 729 cases (36.4%) of retirement, 667 cases of flexible employment or unemployment (33.3%). Education level: 477 cases (23.8%) with bachelor degree or above, 658 cases (32.8%) of high school, 782 cases (39.0%) of elementary or junior high school, 88 cases (4.4%) without education. Marital status: 1789 cases (89.2%) were married, 179 cases (8.9%) divorced or widowed, 37 cases (1.8%) unmarried. Two hundred and ninety-four patients (14.7%) had metastasis when they were first diagnosed, including 203 liver metastases, 52 peritoneal metastases, and 39 other metastases. One thousand eight hundred and sixty-nine patients underwent surgical treatment, of whom 1642 (81.9%) achieved complete resection. The median time of taking imatinib was 25 (1-200) months. Common adverse reactions of imatinib included 1701 cases (84.8%) of periorbital edema, 1031 cases (51.4%) of leukopenia, 948 cases (47.3%) of fatigue, 781 cases (39.0%) of nausea and vomiting, 709 cases (35.4%) of rash, and 670 cases (33.4%) of lower extremity edema. The score of the Morisky Medication Adherence Scale showed that 392 cases (19.6%) had poor adherence, 1023 cases (51.0%) had moderate adherence, and 590 cases (29.4%) had good adherence. Univariate analysis showed that gender, age, work status, economic income, residence, education level, marriage, the duration of taking medication and adverse reactions were associated with adherence to adjuvant imatinib therapy (all P<0.05). Multivariate analysis showed that female (OR=1.264, P=0.009), non-retirement (OR=1.454, P=0.001), monthly income ≤4000 yuan (OR=1.280, P=0.036), township residents (OR=1.332, P=0.005), unmarried or divorced or widowed (OR=1.362, P=0.026), the duration of imatinib medication >36 months (OR=1.478, P<0.001) and adverse reactions (OR=1.719, P=0.048) were independent risk factors for poor adherence to adjuvant imatinib. Among patients undergoing complete resection, 324 (19.7%) had poor adherence, 836 (50.9%) had moderate adherence, and 482 (29.4%) had good adherence. Meanwhile, 55 patients with good adherence (11.4%) developed recurrence after surgery, 121 patients with moderate adherence (14.5%) developed recurrence, 61 patients with poor adherence (18.8%) developed recurrence, and the difference was statistically significant (P=0.017). Conclusions: The adherence to adjuvant therapy with imatinib in Chinese GIST patients is relatively poor. Females, non-retirement, monthly income ≤4000 yuan, township residents, unmarried or divorced or widowed, the duration of imatinib medication >36 months, and adverse reactions are independently associated with poor adherence of GIST patients. Those with poor adherence have a higher risk of recurrence after surgery. Positive interventions based on the above risk factors are advocated to improve the prognosis of patients with GIST.
Aged
;
Aged, 80 and over
;
Antineoplastic Agents/therapeutic use*
;
Chemotherapy, Adjuvant
;
Cross-Sectional Studies
;
Female
;
Gastrointestinal Stromal Tumors/drug therapy*
;
Humans
;
Imatinib Mesylate/therapeutic use*
;
Male
;
Middle Aged
;
Neoplasm Recurrence, Local/drug therapy*
9.Nuclear m
Chuan CHEN ; Wenqiang LIU ; Jiayin GUO ; Yuanyuan LIU ; Xuelian LIU ; Jun LIU ; Xiaoyang DOU ; Rongrong LE ; Yixin HUANG ; Chong LI ; Lingyue YANG ; Xiaochen KOU ; Yanhong ZHAO ; You WU ; Jiayu CHEN ; Hong WANG ; Bin SHEN ; Yawei GAO ; Shaorong GAO
Protein & Cell 2021;12(6):455-474
N
10.Correction to: Nuclear m6A reader YTHDC1 regulates the scaffold function of LINE1 RNA in mouse ESCs and early embryos.
Chuan CHEN ; Wenqiang LIU ; Jiayin GUO ; Yuanyuan LIU ; Xuelian LIU ; Jun LIU ; Xiaoyang DOU ; Rongrong LE ; Yixin HUANG ; Chong LI ; Lingyue YANG ; Xiaochen KOU ; Yanhong ZHAO ; You WU ; Jiayu CHEN ; Hong WANG ; Bin SHEN ; Yawei GAO ; Shaorong GAO
Protein & Cell 2022;13(6):470-471